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Abstract
Background: PTEN is an important tumour suppressor gene that is mutated in Cowden syndrome as well as
various sporadic cancers. CpG island hypermethylation is another route to tumour suppressor gene inactivation,
however, the literature regarding PTEN hypermethylation in cancer is controversial. Furthermore, investigation of
the methylation status of the PTEN CpG island is challenging due to sequence homology with the PTEN
pseudogene, PTENP1. PTEN shares a CpG island promoter with another gene known as KLLN. Here we present a
thorough reinvestigation of the methylation status of the PTEN CpG island in DNA from colorectal, breast, ovarian,
glioma, lung and haematological cancer cell lines.
Results: Using a range of bisulphite-based PCR assays we investigated 6 regions across the PTEN CpG island. We
found that regions 1-4 were not methylated in cancer cell lines (0/36). By allelic bisulphite sequencing and
pyrosequencing methylation was detected in regions 5 and 6 in colorectal, breast and haematological cancer cell
lines. However, methylation detected in this region was associated with the PTENP1 promoter and not the PTEN
CpG island.
Conclusions: We show that methylation of the PTEN CpG island is a rare event in cancer cell lines and that
apparent methylation most likely originates from homologous regions of the PTENP1 pseudogene promoter. Future
studies should utilize assays that reliably discriminate between PTEN and PTENP1 to avoid data misinterpretation.
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Background
Phosphatase and tensin homologue (PTEN) is a tumour
suppressor gene with dual protein and lipid phosphatase
activity. The main mechanism by which PTEN functions
as a tumour suppressor is by negatively regulating the
PI3K-AKT-mTOR pathway [1,2]. Inactivating germline
mutations of PTEN result in a group of rare syndromes
collectively known as the PTEN hamartoma tumour
syndromes (PHTS), which includes Cowden syndrome
and Bannayan-Zonana syndrome [3]. Germline muta-
tions of PTEN account for approximately 80% of Cow-
den syndrome cases [4]. This syndrome is characterised
by a range of clinical features including an increased
risk of breast, thyroid and endometrial cancers [3].
Mutation of the PTEN tumour suppressor gene also
occurs in various sporadic cancers, including 38% of
endometrial, 14% of prostate, 7% of colorectal and 5% of
lung carcinomas [5].
Promoter CpG island hypermethylation, which can
result in the transcriptional silencing of gene expression,
is an alternative mechanism of gene inactivation. The
importance of PTEN inactivation in PHTS and several
types of sporadic cancers makes the gene an attractive
candidate for epigenetic inactivation. The PTEN CpG
island is shared with another gene, known as KLLN,
which is transcribed from the negative DNA strand in
the opposite direction. There are a number of methodo-
logical challenges associated with the detection of
methylation at the PTEN CpG island and in determining
the consequences of methylation on the expression of
PTEN. These challenges arise due to the fact that the
PTENP1 pseudogene (also known as PTEN2), shares
9 7 . 8 %s e q u e n c ei d e n t i t yw i t ht h ePTEN mRNA
sequence, and 91% identity with a 921 bp region of the
PTEN CpG island. Consequently, without careful con-
sideration of assay design there is a possibility of
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The PTENP1 pseudogene is a single exon gene located
at 9p13.3 (genomic coordinates chr9:33,663,502-
33,667,418, NCBI36/hg18, March 2006 freeze). The exis-
tence of the PTENP1 pseudogene has been known for
some time [6,7] and is thought to have arisen due to
retrotransposition to form an intronless copy of the
PTEN gene. Though some earlier reports suggested
PTENP1 is not transcribed [7], more recent data sug-
gests that the PTENP1 mRNA is ubiquitously expressed
in both normal and cancer specimens [8-11]. One study
showed that PTENP1 m R N Al e v e l sm a yb ea sh i g ha s
70% of PTEN mRNA levels [8]. As a consequence of
PTENP1 expression, accurate analysis of PTEN mRNA
levels can be problematic and careful consideration of
assay design is required. Most previous studies have
chosen to analyse PTEN expression using immunohisto-
chemistry [12,13], however, PTEN-specific RT-PCR
assays that utilise sequence variations between the
PTEN and PTENP1 genes have been described [14].
There have been occasional reports of PTEN promoter
hypermethylation in cancer. Marsit et al.r e p o r t e d
hypermethylation of a region of the PTEN CpG island
that is not homologous to PTENP1 in 26% (39/151) of
non-small cell lung cancers (NSCLC), however promoter
methylation was not a strong predictor of reduced or
absent PTEN protein expression. Interestingly, in the
same study, PTENP1 promoter hypermethylation was
found in 66% (112/169) of NSCLCs, but not in normal
peripheral blood DNA [12]. Hypermethylation of two
CpG sites within the PTEN CpG island was also
reported in the peripheral blood of up to 62% of
patients with metastatic melanoma [15], however,
methylation and expression of the PTENP1 gene was
not addressed in this study.
Recently, a study using constitutional DNA from 123
Cowden and Cowden-like syndrome patients without
PTEN mutations reported hypermethylation of a specific
region of the PTEN CpG island located within the 5’
UTR of the PTEN gene [16]. Interestingly, this study
suggested that hypermethylation of this region corre-
lated with downregulation of KLLN expression rather
than PTEN expression. Inactivation of KLLN expression
in patients with sporadic renal cell carcinomas by CpG
island hypermethylation was later proposed in another
study from the same laboratory [17]. Recent evidence
suggests the KLLN gene is necessary for p53-induced
apoptosis and may therefore possess tumour suppressor
function [18].
Several studies have described how differences in the
sequences of PTEN and PTENP1 can be misinterpreted
as PTEN mutations [19]. Furthermore, one previous
study demonstrated that methylation of the PTENP1
gene can also be misinterpreted as methylation of the
PTEN CpG island [20]. In the current study we present
a thorough reinvestigation of the PTEN CpG island to
assess whether hypermethylation occurs in cancer and
to specifically address some of the methodological chal-
lenges associated with the analysis of methylation at this
CpG island.
Results
Methylation analysis of the PTEN CpG island
We designed bisulphite-based PCR assays to determine
the methylation status of six regions (designated regions
1-6) within the PTEN CpG island. The regions exam-
ined for methylation, the position of these regions rela-
tive to the PTEN and KLLN genes, and the type of assay
used are described in Figure 1 and Table 1. These
regions encompassed the majority of the PTEN CpG
island and included the KLLN and PTEN transcription
start sites (TSS). Regions 1-4 are not homologous to the
PTENP1 pseudogene whereas regions 5 and 6 show
97.6% and 95.8% homology with the 5’ region of the
PTENP1 pseudogene. The methylation status of these
regions was investigated using a range of methods, each
with different sensitivities for methylation detection.
These included combined bisulphite restriction analysis
(COBRA), allelic bisulphite sequencing, bisulphite pyro-
sequencing and quantitative real-time methylation-speci-
fic PCR (qMSP). Using COBRA we found that the KLLN
gene body (region 1), as well as the KLLN and PTEN
TSS (region 3) were completely unmethylated in all 36
cancer cell lines analysed (Figure 2). We confirmed
these results using allelic bisulphite sequencing (data
not shown). Using bisulphite pyrosequencing we then
Figure 1 The PTEN CpG island and locations of the regions
assayed for methylation in this study. The PTEN CpG island
(green bar) encompasses a bidirectional promoter from which the
KLLN (blue bar) and PTEN (brown bar) genes are transcribed from
the same transcription start site. The PTEN gene is transcribed from
the positive strand whereas the KLLN gene is transcribed from the
negative strand in the opposite direction. The black bars indicate
the regions analysed for methylation using bisulphite based PCR
assays (see Table 1 for assays, exact position of amplicons and
primer sequences). The red vertical lines within the black bars
indicate restriction endonuclease sites used to assay for methylation
by COBRA. Indicated by the thin black vertical lines are the locations
of CG dinucleotides. Also indicated is a region of the PTEN CpG
island encompassing 921 bp which shows 91% sequence identity
with the 5’ region of the PTENP1 pseudogene located at 9p13.3. *
For region 5, primers were taken from Bennett et al. [16]. These
primers bind sequence that are identical in both the PTEN and
PTENP1 genes producing 283 bp and 291 bp amplicons respectively
and the HpyCH4IV restriction site used assay for methylation using
COBRA is conserved.
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TSS of these genes (region 2). This assay also showed
that all cancer cell lines were unmethylated (Figure 3A),
thus confirming our COBRA and bisulphite sequencing
data across the same region. Next we examined region 4
downstream of the PTEN TSS using qMSP, which has a
methylation detection sensitivity level several orders of
magnitude higher than COBRA and bisulphite pyrose-
quencing. Despite this increased sensitivity we again
observed that all 36 cancer cell lines were unmethylated
(data not shown). We then examined the regions of the
PTEN CpG island most similar in sequence to the pro-
moter region of the PTEN pseudogene (regions 5 and
6). Region 5 was examined using allelic bisulphite
sequencing whereas region 6 was examined using a
bisulphite pyrosequencing assay encompassing six CpG
sites. Interestingly, using these assays we found methyla-
tion in five out of eight cancer cell lines (Figure 3B).
These cell lines were RKO and SW48 (colorectal), Raji
and U937 (haematological) and MDA-MB-231 (breast).
However, given the similarity of these regions to the
Table 1 Primer sequences, regions examined for methylation, and the methods used to detect methylation
Region Method Position Size
(bp)
Forward primer
(5’-3’)
Reverse primer
(5’-3’)
Pyrosequencing
primer (5’-3’)
1 COBRA
Bisulphite sequencing
-966 to -733 233 AGTTTGGTTTYGGGYGATTTAT
TTTGT
CCCAAAAAACACCTATCTAAATA
AACT
2 Bisulphite
pyrosequencing
-110 to
+217
327 TTATGGTTGTAGTTTTYGAGAG
GAGAGAAT
CTACAAAAACCRCAACAAATAC
AACTACAAACTAA (round 1)
CCCAAACAACTACACTAAACAT
ACTCAA (nested)
GAGAGGAGAGAATTG
3 COBRA
Bisulphite sequencing
-80 to +234 314 TTTAGTAGAGTTTGTGGTTTGG
GGATTT
CAAACTTCCATCATAACTACAA
CTTCC
4 qMSP +237 to
+368
132 AGTTGAGTCGTTGTGAGGCGA
GGTCG
CAAACCGACCGACTCCCCGAAAACG
5 Bisulphite sequencing +554 to
+836
283 GTTGTAGTTTTAGGGAGGGGGT CRCCRCTACCAAACCTCTAACTACTA
6 Bisulphite sequencing
Bisulphite
pyrosequencing
+801 to
+971
171 GGTTTTTTTTGTAGGATGGAAA
TGGT
CRCCRCTACCAAACCTCTAACTACTA AAATGGTTTTGGATTT
Six regions of the PTEN CpG island were investigated for methylation in this study using various methods. Listed are the regions assayed, the method used for
the detection of DNA methylation, the position of the region analysed relative to the transcription start site of the PTEN gene (NM_000314) located at
Chr10:89613175 (NCBI36/hg18, March 2006 freeze), the size of each amplicon, and primer sequences (including pyrosequencing primer sequences)
Figure 2 Methylation analysis of the PTEN CpG island using
COBRA. Two regions of the PTEN CpG island were investigated for
methylation using COBRA and were designated regions 1 and 3 as
indicated in Figure 1. A, Region 1 was assayed for methylation using
the restriction endonuclease AatII. Identical results were also
obtained using the restriction endonuclease ClaI. B, Region 3 was
assayed for methylation using the restriction endonuclease TaqI.
Identical results were also obtained using the restriction
endonuclease MluI. No methylation was found in any sample
tested. For each region we used M.SssI in vitro methylated normal
blood DNA as a positive (+ve) control. -, undigested PCR product; +,
digested PCR product.
Figure 3 Bisulphite pyrosequencing analysis of the PTEN CpG
island. Shown are representative pyrograms of region 2 (panel A)
and region 6 (panel B) of the PTEN CpG island from the colorectal
cancer cell line RKO. A, Region 2 was completely unmethylated in
all samples tested. B, Region 6 showed a mean of 12% methylation
across the 6 CpG sites tested in the colorectal cancer cell line RKO.
Indicated by the black arrow is the presence of an A nucleotide
variant specific to the PTENP1 pseudogene suggesting non-specific
amplification of PTENP1. Blue boxes indicate the percent
methylation at each CpG site. Grey shading indicates the CpG sites
tested. Yellow shading indicates bisulphite conversion control
dispensations, which indicated complete conversion in all samples
tested.
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determined whether the methylation observed was attri-
butable to non-specific amplification of the homologous
PTENP1 region. Indeed, closer inspection of the pyro-
grams revealed the presence of an adenine nucleotide
peak at the exact position of a thymine to adenine trans-
version specific to the PTENP1 pseudogene (shown by
the black arrow in Figure 3B). The presence of this ade-
nine peak suggested that PTENP1 alleles were also
amplified using these assays. To confirm whether this
was the case, and to determine whether PTENP1 alleles
could account for the observed methylation, we per-
formed allelic bisulphite sequencing at both regions. We
u t i l i s e ds e v e r a ls i n g l en u c l e o t i d es e q u e n c ed i f f e r e n c e s
between PTEN and PTENP1 within these regions to dis-
criminate PTEN alleles from PTENP1 alleles. We found
that non-specific amplification of the PTENP1 pseudo-
gene accounted for up to 44% and 22% of alleles ampli-
fied using the assays at regions 5 and 6 respectively.
Furthermore, methylation was specifically associated
with PTENP1 alleles whereas all PTEN alleles were
unmethylated (Figure 4).
Discussion
In this study, we present a thorough reinvestigation of
the methylation status of the PTEN CpG island in an
extensive cohort of cancer cell lines. Using a range of
methods including COBRA, bisulphite pyrosequencing,
allelic bisulphite sequencing and qMSP we show that
hypermethylation of this CpG island in cancer cell lines
is rare. These techniques allow the detection of methyla-
tion within individual alleles, as well as the quantitative
measurement of methylation at individual CpG dinu-
cleotides with extremely high sensitivity. Despite this
meticulous analysis, all cell lines analysed were
unmethylated. Our assays spanned the majority of the
PTEN CpG island including the PTEN and KLLN TSS,
the PTEN and KLLN gene bodies, as well as regions pre-
viously reported as hypermethylated [16,17]. We utilised
allelic bisulphite sequencing and sequence variations
between the PTEN and PTENP1 gene to unequivocally
demonstrate that apparent methylation of the PTEN
CpG island is actually attributable to the non-specific
amplification of the highly homologous PTENP1 gene.
T h ec h a l l e n g e sp o s e db ys e q u e n c eh o m o l o g yw i t h
pseudogenes are by no means particular to the PTEN
gene. Another example is the DNA mismatch repair
gene postmeiotic segregation increased 2 (PMS2) gene,
which shares at least 95.2% sequence identity with six
other genes (PMS2CL, PMS2L2, PMS2P4, PMS2P5,
PMS2P1, PMS2P11)a sw e l la saf u r t h e r1 0s i t e s ,a l lo n
chromosome 7. Importantly, the PMS2 CpG island
shares over 87.5% sequence identity encompassing at
least 849 bp of the 5’ regions of the PMS2L5, PMS2P4,
PMS2L2 and PMS2P1 genes. This makes the methyla-
tion analysis of the PMS2 CpG island particularly
challenging.
There are a number of methodological strategies that
can be employed to prevent the misinterpretation of
data when investigating the methylation status of a gene
with a pseudogene. When designing assays for a given
gene, the existence of a pseudogene or other regions of
high sequence homology should first be determined
using in silico sequence analysis of the mRNA and CpG
island sequences. Following sequence comparisons
assays should utilise critical sequence variations that
allow the specific amplification of the gene of interest,
or regions of high homology can be avoided completely.
Newly designed assays must always be validated using
methods that can discriminate between individual
alleles. This is most easily achieved using allelic bisul-
phite sequencing. It is also crucial to be aware of ampli-
con sizes given that multiple amplicons or unexpected
amplicon sizes can indicate non-specific amplification of
related sequences such as pseudogenes. Finally, we
recommend that the methylation status of regions with
particularly high homology to pseudogenes can only be
determined using allelic bisulphite sequencing to allow
the identification of pseudogene-specific alleles.
Conclusions
We show that somatic hypermethylation of the PTEN
CpG island is rare in cancer cell lines. Our study
demonstrates the technical challenges associated with
analysing the methylation status of the PTEN CpG
island and suggests methodological strategies for study-
ing the methylation status of genes with pseudogenes,
such as PTEN. It is imperative that the methodological
challenges outlined in this study are taken into account
when interpreting the data from previous and future
studies of the PTEN CpG island.
Methods
Sample details and DNA extraction
DNA from 36 cancer cell lines was extracted using the
standard phenol-chloroform method. These included 20
colorectal (RKO, SW48, HT-29, Lim1215, SW480, SNU-
C2B, Lim2412, SW620, Lim2405, DLD1, HCT116, HCT-
15, LoVo, LS147T, Colo 320 DM, LS411, Caco-2, SW948,
HCT8, COLO 205), 3 breast (MCF-7, SK-BR-3, MDA-
MB-231), 6 haematological (Raji, U937, K562, KG1, MF-1,
Kasumi-1), 4 ovarian (OVCAR-3, TOV-112D, TOV-21 G,
EF027) one glioma (U251), one embryonal carcinoma
(NCCIT) and one lung (A549) cancer cell line
Sodium bisulfite modification
Genomic DNA was treated with sodium bisulphite using
the EZ DNA Methylation-Gold kit (Zymo Research,
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Page 4 of 8Figure 4 DNA methylation is specifically associated with PTENP1 and not the PTEN CpG island. A,R e p r e s e n t a t i v es e q u e n c i n gd a t ao f
region 6 from the haematological and colorectal cancer cell lines Raji and RKO. Only PTENP1 derived alleles showed DNA methylation. Each line
represents a single allele. Circles indicate the positions of CpG dinucleotides; black circles indicate methylated CpG dinucleotides; white circles
indicate unmethylated CpG dinucleotides; yellow diamonds indicate the positions of nucleotide variations within PTENP1 alleles used to
discriminate between PTEN and PTENP1 alleles. B, Representative electropherograms from region 6 showing an unmethylated PTEN allele and a
methylated PTENP1 allele from the colorectal cancer cell line RKO. Indicated by the black arrow is the position of a variant nucleotide which was
used to discriminate between PTEN and PTENP1 alleles (the same nucleotide indicated by the black arrow in Figure 3B). CpG dinucleotides are
boxed in red. C, Allelic bisulphite sequencing of region 5 in the cancer cell lines Raji and RKO. Again, only PTENP1 derived alleles showed
methylation. Sequence variations used to discriminate between PTEN and PTENP1 alleles are indicated by yellow diamonds. Black diamonds
indicate the positions of additional CpG dinucleotides specific to PTENP1 alleles that were also methylated. D, Representative electropherograms
from region 5 showing an unmethylated PTEN allele and a methylated PTENP1 allele from the cell line Raji. Indicated by the black arrow is the
position of a nucleotide variation used to discriminate the PTEN and PTENP1 alleles.
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instructions. A measure of 1-1.5 μg DNA was incubated
for 10 min at 98°C, followed by 18 hr at 53°C. Bisulphite
converted DNA was eluted in 20-25 μL M-elution buffer
and stored at -20°C until required.
Primer sequences
All primer sequences used throughout this study are
listed in Table 1.
Combined bisulphite restriction analysis
The methylation of two regions of the PTEN CpG island
(regions 1 and 3, Table 1 and Figure 1) were analysed by
COBRA, consisting of sodium bisulphite modification
followed by PCR and restriction digestion [21]. For each
assay, the PCR mixture contained 1x PCR buffer, 0.25
mM each dNTP, 1.5 mM MgCl2,0 . 4μMf o r w a r da n d
reverse primers (Geneworks), and 1.25 U Platinum Taq
polymerase (Invitrogen), and 80-225 ngbisulphite modi-
fied DNA. The PCR mixture for region 1 was subject to
thermocycling at 95°C for 5 min, 40 cycles of 95°C for
30 sec/51°C for 30 sec/72°C for 30 sec, followed by a
final extension of 72°C for 10 min. The PCR mixture for
region 3 was subjected to thermocycling at 95°C for 5
min, 10 cycles of touchdown at 95°C for 30 sec/65°C for
30 sec/72°C for 30 sec, 30 cycles at 95°C for 30 sec/55°C
for 30 sec/72°C for 30 sec, followed by a final extension
of 72°C for 10 min. The PCR mixture for region 3 was
subjected to thermocycling at 95°C for 5 min, 45 cycles
of 95°C for 30 sec/62°C for 30 sec/72°C for 30 sec, fol-
lowed by a final extension of 72°C for 10 min. Prior to
restriction digestion 3 μL of each amplicon was resolved
on a 1.5% agarose gel for quality control. Restriction
digest reactions were carried out in a total volume of 15
μL containing the appropriate 1x restriction enzyme
buffer, 1x BSA if required, 10 U restriction enzyme
(New England Biolabs) and 9.5 μL amplicon. To assay
for methylation the restriction enzymes AatII and ClaI
(region 1) or TaqI and MluI (region 3) were used, each
in separate reactions. For each restriction digest, an
equal amount of amplicon was subject to the same con-
ditions without the addition of restriction enzyme.
Digest reactions with and without restriction enzyme
were resolved in adjacent lanes on a 2% high resolution
agarose gel to prevent background bands from the PCR
reaction from being misinterpreted as digestion, and
therefore methylation. Each assay included a fully
methylated positive control (genomic DNA from a nor-
mal individual methylated with CpG M.SssI methylase),
as well as normal blood DNA.
Quantitative real-time methylation specific PCR
Quantitative real-time methylation-specific PCR was
used to assay for methylation at region 4 (Table 1 and
Figure 1). This assay consists of sodium bisulphite modi-
fication followed by PCR with primers specific to methy-
lated template. The PCR mixture contained 1x iQ™
SYBR Green
® Supermix buffer (Bio-Rad), 0.3 μMf o r -
ward and reverse primers (Geneworks) and 80-120 ng
bisulphite modified DNA. This PCR mixture was sub-
jected to thermocycling at 95°C for 2 min, 42 cycles at
95°C for 30 sec/70°C for sec/72°C for 30 sec, followed
by melt curve analysis from 70°C to 94°C. In addition, a
bisulphite specific control reaction using MyoD mea-
sured the loading of bisulphite converted DNA. The
MyoD reaction is not methylation specific but is specific
for bisulphite converted DNA. The MyoD specific pri-
mers used were 5’- CCAACTCCAAATCCCCTCTC-
TAT-3’ and 5’-TGATTAATTTAGATTGGGTTTA
GAGAAGGA-3’. MyoD MSP was subject to thermocy-
cling at 95°C for 2 min, 42 cycles at 95°C for 30 sec/
58.5°C for 30 sec/72°C for 30 sec/77.5°C for 30 sec, fol-
lowed by melt curve analysis from 70°C to 88.5°C. Abso-
lute values for experimental samples were calculated
from the PCR cycle number at which the fluorescence
crossed the threshold with the use of the standard
curve. Values were normalised against MyoD and the
percentage of methylated alleles was calculated with
reference to 100% in vitro methylated human DNA
(Zymo Research, Orange, CA, USA).
Pyrosequencing
We used pyrosequencing to assay for methylation at two
regions of the PTEN CpG island (regions 2 and 5, Table
1 and Figure 1). Pyrosequencing consisted of sodium
bisulphite modification followed by PCR and pyrose-
quencing with an additional internal primer. In all cases
the reverse primer was labelled with biotin. For region 2
we used semi-nested PCR. Both rounds of PCR con-
tained 1x PCR buffer, 0.25 mM each dNTP, 1.5 mM
MgCl2,0 . 4μM forward and reverse primers and 1.25 U
Platinum Taq polymerase, and 80-120 ng bisulphite
modified DNA. This PCR mixture was subjected to
thermocycling at 95°C for 5 min, 30 cycles at 95°C for
30 sec/61°C for 30 sec/72°C for 30 sec, followed by a
final extension of 72°C for 10 min. For the second
round, 1 μL of the first round PCR was added to a sec-
ond PCR reaction containing the same ingredients but
with a nested reverse primer and subjected to the same
thermocycle as above. For region 5, the PCR mixture
contained 1x PCR buffer, 0.25 mM each dNTP, 1.5 mM
MgCl2,0 . 4μM forward and reverse primers and 1.25 U
Platinum Taq polymerase, and 80-120 ng bisulphite
modified DNA. This PCR mixture was subjected to
thermocycling at 95°C for 5 min, 45 cycles of 95°C for
30 sec/61°C for 30 sec/72°C for 30 sec, followed by a
final extension of 72°C for 10 min. Prior to pyrosequen-
cing 3-5 μl of amplicon were checked on a 1.5% agarose
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immobilized using streptavidin-coated sepharose beads
(Amersham Biosciences) and binding buffer according
to the manufacturer’s instructions. The strands were
separated using a Vacuum Prep Station (Biotage), and
diluted in 40 μl annealing buffer containing 0.4 μM
sequencing primer. The sequencing primers (Table 1)
were annealed to the template at 90°C for 2 min. For
region 2, the nucleotide dispensation order used was
GATGTCGCTATGTCAGTCGCTTATGTCAGTC-
GATGTCAGTCGCTATTAGTCGCTATGTCGCTA.
For region 5, the nucleotide dispensation order used was
TGTCGCTAGTGATAGTTCGTTAGTCTGTCGTGT
TGTATCGCTATGTCG. Pyrosequencing was per-
formed using the PyroGoldReagents (Biotage) and Pyro-
mark ID system (Biotage). The software PyroMark CpG
Software (version 1.0) was used for evaluation of peaks
for methylation by SQA analysis.
Allelic bisulphite sequencing
Individual alleles were cloned and bisulphite sequenced
for regions 1, 3, 5 and 6. Amplicons were cloned into
the pCR
®2.1-TOPO
® vector (Invitrogen) and trans-
formed into TOP10 One Shot Cells or DH5a One Shot
Cells (Invitrogen) according to the manufacturers’
instructions. Following transformation and selection of
bacteria on agar plates we performed colony PCR using
M13 primers. The PCR mixture contained 1x PCR buf-
fer, 0.25 mM each dNTP, 2.5 mM MgCl2,0 . 4μMM 1 3
forward and M13 reverse primers and 1.25 U Platinum
Taq polymerase, and inoculated with part of a discrete
bacterial colony. This PCR mixture was subject to ther-
mocycling at 95°C for 5 min, 35 cycles of 95°C for 30
sec/52°C for 30 sec/72°C for 30 sec, followed by a final
extension of 72°C for 10 min. PCR products were puri-
fied using MultiScreen PCR plates (Millipore) and then
subject to sequencing using the ABI BigDye Cycle
Sequencing kit (Perkin Elmer) using the M13 reverse
primer. Following ethanol precipitation of the sequenced
products, samples were analysed using an ABI 3730
DNA sequencer (Perkin Elmer).
Abbreviations
COBRA: Combined bisulphite restriction analysis; NSCLC: Non small cell lung
cancer; PTEN: Phosphatase and tensin homologue; PTENP1: PTEN
pseudogene 1; PHTS: PTEN hamartoma tumour syndrome; qMSP:
Quantitative real-time methylation-specific polymerase chain reaction; RT-
PCR: Reverse transcriptase polymerase chain reaction; TSS: Transcription start
site; UTR: Untranslated region.
Acknowledgements
This work was funded by grants from the Cancer Council New South Wales
and Cancer Institute New South Wales.
Author details
1Adult Cancer Program, Lowy Cancer Research Centre and Prince of Wales
Clinical School, University of New South Wales, Sydney, NSW 2052, Australia.
2Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic,
Cleveland, OH 44195, USA.
3Department of Genetics and CASE
Comprehensive Cancer Center, Cleveland, OH 44116, USA.
Authors’ contributions
DP and LBH were involved in assay design, as well as acquisition and
analysis of data. LBH and RLW were involved in the study concept, and
interpretation of the data. EP, PF, and CE provided expertise with
methodology. RLW and LBH obtained funding. All authors were involved in
drafting and critical revision of the manuscript and gave final approval of
the version published. All authors read and approve the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 15 March 2012 Accepted: 10 April 2012
Published: 10 April 2012
References
1. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T,
Ruland J, Penninger JM, Siderovski DP, Mak TW: Negative regulation of
PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell
1998, 95:29-39.
2. Wu X, Senechal K, Neshat MS, Whang YE, Sawyers CL: The PTEN/MMAC1
tumor suppressor phosphatase functions as a negative regulator of the
phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci USA 1998,
95:15587-15591.
3. Hollander MC, Blumenthal GM, Dennis PA: PTEN loss in the continuum of
common cancers, rare syndromes and mouse models. Nat Rev Cancer
2011, 11:289-301.
4. Marsh DJ, Coulon V, Lunetta KL, Rocca-Serra P, Dahia PL, Zheng Z, Liaw D,
Caron S, Duboue B, Lin AY, et al: Mutation spectrum and genotype-
phenotype analyses in Cowden disease and Bannayan-Zonana
syndrome, two hamartoma syndromes with germline PTEN mutation.
Hum Mol Genet 1998, 7:507-515.
5. Forbes S, Clements J, Dawson E, Bamford S, Webb T, Dogan A, Flanagan A,
Teague J, Wooster R, Futreal PA, Stratton MR: Cosmic 2005. Br J Cancer
2006, 94:318-322.
6. Teng DH, Hu R, Lin H, Davis T, Iliev D, Frye C, Swedlund B, Hansen KL,
Vinson VL, Gumpper KL, et al: MMAC1/PTEN mutations in primary tumor
specimens and tumor cell lines. Cancer Res 1997, 57:5221-5225.
7. Dahia PL, FitzGerald MG, Zhang X, Marsh DJ, Zheng Z, Pietsch T, von
Deimling A, Haluska FG, Haber DA, Eng C: A highly conserved processed
PTEN pseudogene is located on chromosome band 9p21. Oncogene
1998, 16:2403-2406.
8. Fujii GH, Morimoto AM, Berson AE, Bolen JB: Transcriptional analysis of the
PTEN/MMAC1 pseudogene, psiPTEN. Oncogene 1999, 18:1765-1769.
9. Yokoyama Y, Wan X, Shinohara A, Takahashi S, Takahashi Y, Niwa K,
Tamaya T: Expression of PTEN and PTEN pseudogene in endometrial
carcinoma. Int J Mol Med 2000, 6:47-50.
10. Zhang CL, Tada M, Kobayashi H, Nozaki M, Moriuchi T, Abe H: Detection of
PTEN nonsense mutation and psiPTEN expression in central nervous
system high-grade astrocytic tumors by a yeast-based stop codon assay.
Oncogene 2000, 19:4346-4353.
11. Ioffe YJ, Chiappinelli KB, Mutch DG, Zighelboim I, Goodfellow PJ:
Phosphatase and tensin homolog (PTEN) pseudogene expression in
endometrial cancer: a conserved regulatory mechanism important in
tumorigenesis? Gynecol Oncol 2012, 124(2):340-346.
12. Marsit CJ, Zheng S, Aldape K, Hinds PW, Nelson HH, Wiencke JK, Kelsey KT:
PTEN expression in non-small-cell lung cancer: evaluating its relation to
tumor characteristics, allelic loss, and epigenetic alteration. Hum Pathol
2005, 36:768-776.
13. Baeza N, Weller M, Yonekawa Y, Kleihues P, Ohgaki H: PTEN methylation
and expression in glioblastomas. Acta Neuropathol 2003, 106:479-485.
14. Liu J, Kagan J: Method to distinguish between the MMAC1/PTEN gene
and its pseudogene in RT-PCR analysis of point mutations. Biotechniques
1999, 26:19-22, 24.
15. Mirmohammadsadegh A, Marini A, Nambiar S, Hassan M, Tannapfel A,
Ruzicka T, Hengge UR: Epigenetic silencing of the PTEN gene in
melanoma. Cancer Res 2006, 66:6546-6552.
Hesson et al. Biological Procedures Online 2012, 14:5
http://www.biologicalproceduresonline.com/content/14/1/5
Page 7 of 816. Bennett KL, Mester J, Eng C: Germline epigenetic regulation of KILLIN in
Cowden and Cowden-like syndrome. JAMA 2010, 304:2724-2731.
17. Bennett KL, Campbell R, Ganapathi S, Zhou M, Rini B, Ganapathi R,
Neumann HP, Eng C: Germline and somatic DNA methylation and
epigenetic regulation of KILLIN in renal cell carcinoma. Genes
Chromosomes Cancer 2011, 50:654-661.
18. Cho YJ, Liang P: Killin is a p53-regulated nuclear inhibitor of DNA
synthesis. Proc Natl Acad Sci USA 2008, 105:5396-5401.
19. Whang YE, Wu X, Sawyers CL: Identification of a pseudogene that can
masquerade as a mutant allele of the PTEN/MMAC1 tumor suppressor
gene. J Natl Cancer Inst 1998, 90:859-861.
20. Zysman MA, Chapman WB, Bapat B: Considerations when analyzing the
methylation status of PTEN tumor suppressor gene. Am J Pathol 2002,
160:795-800.
21. Xiong Z, Laird PW: COBRA: a sensitive and quantitative DNA methylation
assay. Nucleic Acids Res 1997, 25:2532-2534.
doi:10.1186/1480-9222-14-5
Cite this article as: Hesson et al.: A reinvestigation of somatic
hypermethylation at the PTEN CpG island in cancer cell lines. Biological
Procedures Online 2012 14:5.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Hesson et al. Biological Procedures Online 2012, 14:5
http://www.biologicalproceduresonline.com/content/14/1/5
Page 8 of 8